Palladium mediated 11C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [11C]AZD9272

Nuclear Medicine and Biology

Volumn 40, Issue 4, 2013, Pages 547-553

  Andersson, Jan D ^a   Seneca, Nicholas ^a   Truong, Phong ^a   Wensbo, David ^b   Raboisson, Patrick ^b   Farde, Lars ^a,b   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Cynomolgus monkeys; Hydrogen 11C cyanide ( 11C HCN); Metabotropic glutamate receptor 5 (mGluR5); Positron emission tomography (PET); Radiochemistry

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 (6 METHYL PYRIDIN 2 YLETHYNYL) CYCLOHEX 2 ENONE O METHYLOXIME; 3 (6 METHYL PYRIDIN 2 YLETHYNYL) CYCLOHEX 2 ENONE O METHYLOXIME C 11; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 FLUORO 5 [3 [5 FLUOROPYRIDIN 2 YL] 1,2,4 OXADIAZOL 5 YL]BENZONITRILE; 3 FLUORO 5 [3 [5 FLUOROPYRIDIN 2 YL] 1,2,4 OXADIAZOL 5 YL]BENZONITRILE C 11; 3 FLUORO 5 [[PYRIDIN 3 YL]ETHYNYL]BENZONITRILE F 18; 3-(6-METHYL-PYRIDIN-2-YLETHYNYL)-CYCLOHEX-2-ENONE O METHYLOXIME; ABP 688; AZD 9272; CARBON 11; METABOTROPIC RECEPTOR 5; PALLADIUM; RADIOLIGAND; UNCLASSIFIED DRUG; AZD9272; CARBON; LIGAND; NITRILE; OXADIAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CAUDATE NUCLEUS; CEREBELLUM; CINGULATE GYRUS; CONTROLLED STUDY; CYANATION; DOSE RESPONSE; DRUG BINDING; DRUG METABOLISM; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HAPLORHINI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; ISOTOPE LABELING; MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; RADIOACTIVITY; RECEPTOR OCCUPANCY; TEMPORAL CORTEX; THALAMUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CATALYSIS; CHEMISTRY; FEASIBILITY STUDY; INJECTION; MACACA FASCICULARIS; METABOLISM; RADIOCHEMISTRY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; DRUG ANTAGONISM;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; CARBON RADIOISOTOPES; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEASIBILITY STUDIES; INJECTIONS; LIGANDS; MACACA FASCICULARIS; NITRILES; OXADIAZOLES; PALLADIUM; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOCHEMISTRY; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84876731792     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.12.012     Document Type: Article

References (32)

1. Spooren W.P., Gasparini F., Salt T.E., Kuhn R. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 2001, 22(7):331-337.
2. Gereau R.W., Conn P.J. Roles of specific metabotropic glutamate-receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability. J Neurophysiol 1995, 74(1):122-129.
3. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34(1):1-26.
4. Kunishima H., Takemura H., Yamamoto H., Kanemitsu K., Shimada J. Evaluation of the activity of antimicrobial agents against Legionella pneumophila multiplying in a human monocytic cell line, THP-1, and an alveolar epithelial cell line, A549. J Infect Chemother 2000, 6(4):206-210.
5. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 2000, 275(43):33750-33758.
6. Romano C., Sesma M.A., McDonald C.T., O'Malley K., Van den Pol A.N., Olney J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995, 355(3):455-469.
7. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000, 295(3):1267-1275.
8. Klodzinska A., Tatarczynska E., Chojnacka-Wojcik E., Nowak G., Cosford N.D., Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 2004, 47(3):342-350.
9. Porter R.H., Jaeschke G., Spooren W., Ballard T.M., Buttelmann B., Kolczewski S., et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005, 315(2):711-721.
10. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 1998, 56(1-2):207-217.
11. Rouse S.T., Marino M.J., Bradley S.R., Awad H., Wittmann M., Conn P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 2000, 88(3):427-435.
12. Breysse N., Baunez C., Spooren W., Gasparini F., Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002, 22(13):5669-5678.
13. Armentero M.T., Fancellu R., Nappi G., Bramanti P., Blandini F. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis 2005.
14. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001, 4(9):873-874.
15. Notenboom R.G., Hampson D.R., Jansen G.H., van Rijen P.C., van Veelen C.W., van Nieuwenhuizen O., et al. Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients. Brain 2006, 129(Pt 1):96-107.
16. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38(10):1493-1503.
17. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003, 46(2):204-206.
18. 3H]MethoxyPyEP, an mGluR5 selective radioligand. Life Sci 2003, 73(3):371-379.
19. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 2002, 303(3):1044-1051.
20. 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006, 47(4):698-705.
21. Hamill T.G., Krause S., Ryan C., Bonnefous C., Govek S., Seiders T.J., et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005, 56(4):205-216.
22. Raboisson P., Breitholtz-Emanuelsson A., Dahllöf H., Edwards L., Heaton W.L., Isaac M., et al. Discovery and characterization of AZD9272 and AZD6538 - two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg Med Chem Lett 2012, 22:6974-6979.
23. 11C reaction (XV). Int J Appl Radiat Isotopes 1975, 26:435-442.
24. 11C-cyanation. J Labeled Compounds Radiopharm 2008, 51:1-5.
25. 11C]cyanide in synthesis of 11C-labelled aromatic compounds. J Chem Soc Perkin Trans 1994, 1:1395-1400.
26. Clark J.D., Gebhart G.F., Gonder J.C., Keeling M.E., Kohn D.F. Special report: the, guide for the care and use of laboratory animals. ILAR J 1996, 38(1):41-48.
27. 1-dopamine receptor. Psychopharmacology (Berl) 1993, 113:149-156.
28. Wienhard K., Dahlbom M., Eriksson L., Michel C., Bruckbauer T., Pietrzyk U., et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994, 18(1):110-118.
29. 11C]raclopride binding. J Cereb Blood Flow Metab 1998, 18(9):941-950.
30. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989, 9:696-708.
31. Halldin C., Swahn C., Farde L., Sedvall G. Radioligand disposition and metabolism - key information in early drug development. PET for drug development and evaluation 1995, 55-65. Klüwer Academic Publishers, Dordrecht. D. Comar (Ed.).
32. 11C-ABP688. J Nucl Med 2007, 48(2):247-252.